Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | KCNT1 | Q5JUK3 | 7/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.36 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842135 | 1.00 | BRPF1 (0.43) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1839208 | 1.00 | BRPF1 (0.43) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1840778 | 0.93 | BRPF1 (0.41) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1842002 | 0.93 | BRPF1 (0.41) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1843752 | 0.92 | BRPF1 (0.41) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1841106 | 0.92 | BRPF1 (0.41) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1841102 | 0.92 | BRPF1 (0.41) | BRPF1CDK2AKT1KCNT1DGAT2 | |
| SCHEMBL1843009 | 0.90 | BRPF1 (0.43) | BRPF1KCNT1MGLLDDR2KCNQ1 | |
| SCHEMBL1844278 | 0.90 | BRPF1 (0.54) | BRPF1KCNT1MGLLDDR2KCNQ1 | |
| SCHEMBL1838894 | 0.90 | BRPF1 (0.43) | BRPF1KCNT1MGLLDDR2KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | claimed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | claimed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | BRPF1 1691/4885CDK2 1528/4885AKT1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.